Clinical Trial Protocol Information

Clinical trial protocol information for active or completed studies are available below.

If you are a patient, physician, or researcher seeking more information about Takeda’s active or completed clinical trials in the Japanese language please click here.


All Clinical Trial Protocol Information

Search

C26004

A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma...
www.clinicaltrials.gov/ct2/show/NCT02391038

Febuxostat XR-1010

A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to Assess the Effect of an Antacid on the Bioavailability of Febuxostat After Oral Administration of a 80 mg Febuxo...
www.clinicaltrials.gov/ct2/show/NCT02382640

MT203/CPH-001

A Randomized, Single-center, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety and Pharmacokinetics of Single Subcutaneous Injection of MT203 in Healthy Adult Japanese and Caucasian Ma...
www.clinicaltrials.gov/ct2/show/NCT02354599

M1-1188_202

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexat...
www.clinicaltrials.gov/ct2/show/NCT02379091

Febuxostat XR-1009

A Phase 1, Open-Label, Single-Center, Randomized, 3-Way Crossover Study to Assess the Effect of Food on the Bioavailability of a Single Oral Dose of 80 mg Febuxostat Extended-Release Formulation and t...
www.clinicaltrials.gov/ct2/show/NCT02374164

C34002

An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukem...
www.clinicaltrials.gov/ct2/show/NCT02323113

MLN3126_103

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 i...
www.clinicaltrials.gov/ct2/show/NCT02209506

C26003

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
www.clinicaltrials.gov/ct2/show/NCT02202785